Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group.
about
Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infectionThird trimester antiviral therapy for preventing recurrent genital herpes at deliveryOral acyclovir suppression and neurodevelopment after neonatal herpesImpact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infectionValacyclovir for the prevention of recurrent herpes simplex virus eye disease after excimer laser photokeratectomy.Genital herpes.Improving the management of genital herpes.Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis.Recent advances in management of genital herpes.Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled studyResistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and managementClinical Evidence: Genital herpesSexually transmitted diseases treatment guidelines, 2015.Valacyclovir in the treatment of genital herpes and herpes zoster.Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster.Valacyclovir for the treatment of genital herpes.Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.Progress in meeting today's demands in genital herpes: an overview of current management.Clinical manifestations and treatment considerations of herpes simplex virus infection.Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpesPatient satisfaction with care for genital herpes: insights from a global survey.Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations.Emerging therapies for herpes viral infections (types 1 - 8).Antiviral therapy for genital herpes infections in pregnancy.Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.Contemporary antiviral drug regimens for the prevention and treatment of orolabial and anogenital herpes simplex virus infection in the normal host: Four approved indications and 13 off-label uses.Current use of anti-infectives in dermatology.Rise in seroprevalence of herpes simplex virus type 1 among highly sexual active homosexual men and an increasing association between herpes simplex virus type 2 and HIV over time (1984-2003).Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients.Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacologyCorrelation between pill counts and biologic effects in an HIV-1 prevention clinical trial: implications for measuring adherenceEffect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trialSuppressive valacyclovir therapy to reduce genital herpes transmission: good public health policy?Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovirEvaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs.Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases.Valacyclovir: approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults.Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options.Sexually transmitted diseases in women. Chlamydia trachomatis and herpes simplex infections.Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention.
P2860
Q24242853-58DFE577-D7D1-4D84-BCD0-5DA1916936C1Q24246421-0532D6E2-CC28-4449-AEE7-45497D3EEB5AQ24615077-50393B1B-4659-4269-A5E2-444F296C00FCQ24671668-CEA64BF8-BCDE-4263-A49B-8DB6F40EBFE7Q30979930-2D82B696-3982-4B1F-9747-A0F6AB75FC8FQ33448071-BF42B532-533F-43A7-80C2-4FE1CB4C8430Q33536654-E3FD15A7-4BB9-42A8-B1C6-53894E4D2EF7Q33981154-273F3B84-9626-4ED8-9641-5C0DA9B66716Q34012149-420F8379-5500-47BF-BF30-1BE10AAA6631Q34144914-F6F38833-D639-43EC-8A61-8A2253AD8F45Q34149904-F5C47DB1-3BD2-42DC-8B98-587679E3BABAQ34190888-FC624D83-5264-4C39-AFA0-D5F96A79914DQ34479272-78B065E5-581D-4CC8-9A25-6044411A5532Q34482036-2479F79F-0E33-4A32-B58E-8978766B7359Q34551831-D0CAC773-286E-48EA-B47C-D41377209AD3Q34568338-45E8387D-BE0B-4BBC-B953-49B3FFE753E7Q34918273-D5433218-40AB-4470-90EC-08D202460461Q34918299-318EC221-61B6-418A-B05B-E10080C56638Q34918343-62DDD803-E062-4578-B872-8DAB208D1869Q35230156-00862479-6670-4DDA-A991-C85542E0042DQ35531277-40AA761C-FF5E-426F-BC76-62D4B2C58C47Q35941348-B5F8230A-4A45-48E9-92E9-6378400AC122Q35967376-5CDDC264-6460-4125-A9EE-76F48038A7E0Q36162365-22114A28-905A-4A2A-AEFF-226E43D99291Q36167255-690B470C-ED51-4425-869C-2C0DCDD98FD4Q36170672-F6101FC4-9F64-43AB-970E-7494DFFAB6CDQ36233506-BA7CBDC7-28C9-4DB1-9ADD-39766C8C4C65Q36360870-54C3EB1F-2CD5-4273-8677-90D3435D0F9AQ36644718-8B026125-F67F-4308-A31C-E5B24D876D65Q36823598-62281310-6481-45F6-91D5-36E85FE07DA9Q37042078-E1AF0B38-3A4B-47F0-BCBD-C015DBCB8BE6Q37114698-39D9D542-C20D-441B-B01C-0649A85C52C7Q37206230-19CC7245-1EC0-451D-99C1-AAABE7DC58EBQ37229605-91F63323-2442-42E6-96B3-82BA86F2642FQ37283124-16B85911-FD56-4EBA-A692-129BC18E7A30Q37355008-375169FE-7EA0-4B56-B000-8610552283A5Q37763929-EC1C12F5-C076-4D30-AD1E-AA233AB9CD95Q37771396-C405863A-D472-40EF-9B68-B969D4139FFAQ37877139-BE42152E-C198-42CA-9ED4-1FE125B272D2Q38049148-37A08F50-87F8-449B-A1CF-1D758F516215
P2860
Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Valaciclovir for the suppressi ...... Valaciclovir HSV Study Group.
@en
Valaciclovir for the suppressi ...... Valaciclovir HSV Study Group.
@nl
type
label
Valaciclovir for the suppressi ...... Valaciclovir HSV Study Group.
@en
Valaciclovir for the suppressi ...... Valaciclovir HSV Study Group.
@nl
prefLabel
Valaciclovir for the suppressi ...... Valaciclovir HSV Study Group.
@en
Valaciclovir for the suppressi ...... Valaciclovir HSV Study Group.
@nl
P2093
P356
P1476
Valaciclovir for the suppressi ...... Valaciclovir HSV Study Group.
@en
P2093
Chambers LO
Robinson JM
P304
P356
10.1086/515385
P407
P577
1998-09-01T00:00:00Z